AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 221 min read

Unicycive Therapeutics, Inc. (UNCY) OLC NDA Accepted; PDUFA March 25, 2027

Unicycive Therapeutics (UNCY) announced FDA acceptance of its oxylanthanum carbonate NDA resubmission, with a PDUFA date set for March 25, 2027. The filing addresses manufacturing concerns raised in a 2026 CRL, according to the company.

Original reporting
tradingview.com
Published Oct 22, 2026, 12:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 12:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Unicycive Therapeutics, Inc. (UNCY) OLC NDA Accepted; PDUFA March 25, 2027 — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The FDA acceptance removes a regulatory hurdle and sets a clear PDUFA date, which could drive speculative interest.

02

Market read

First report of FDA acceptance provides a fresh catalyst for the stock, though the approval timeline extends to 2027.

03

What to watch

The third‑party manufacturer change may introduce new supply‑chain risks.

Relevance 8/10Novelty 8/10Timing: today

Background

Unicycive Therapeutics filed a Class II NDA resubmission for oxylanthanum carbonate after a CRL in June 2026.

Market effects

Sector

Potential boost for biotech sector as FDA acceptance signals progress.

Regional

Limited to US biotech investors; no broad regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Approval still uncertain; delays or additional data requests could negate any upside.

Key entities

  • company
    Unicycive Therapeutics, Inc.

    Biotech firm pursuing FDA approval for oxylanthanum carbonate.

Read at source← All news

StoryFDA accepts Unicycive's renewed kidney-drug filing and sets March 25, 2027 decision date

Also covered by

4 outlets

Related articles

OCT 22
$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.

investing.com2 min
OCT 21
$UNCYMedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA acceptance of its resubmitted NDA for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a PDUFA date of March 25, 2027. The resubmission includes new manufacturing data. The company hopes for potential approval, pending FDA review and possible inspections.

insidermonkey.com2 min
OCT 21
$UNCYHighAI 8/10

Why is Unicycive Therapeutics stock rallying today?

Unicycive Therapeutics (UNCY) stock rose 3.5% after the FDA accepted its resubmission for oxylanthanum carbonate, a treatment for chronic kidney disease. The FDA set a March 2027 target action date. The resubmission includes new manufacturing data addressing prior deficiencies. The broader market also gained, supporting small-cap biotech stocks. The company faces ongoing legal action, capping gains.

investing.com1 min
OCT 21
$UNCYHigh

Unicycive stock jumps as FDA accepts OLC drug resubmission

Unicycive Therapeutics (UNCY) shares rose 6.8% premarket after the FDA accepted its resubmission for oxylanthanum carbonate, a drug for chronic kidney disease. The FDA set a March 25, 2027, target action date. The resubmission includes new manufacturing data from a third-party vendor. The company aims for FDA approval via the 505(b)(2) pathway.

investing.com2 min
OCT 21
$UNCYMed

FDA accepts Unicycive resubmission for kidney disease drug

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmission for oxylanthanum carbonate, a drug for chronic kidney disease. The FDA set a target action date of March 25, 2027, and the resubmission includes data from a new manufacturing vendor. The company received a Complete Response Letter in June 2026 due to issues with the original manufacturer. Unicycive seeks approval via the 505(b)(2) pathway.

investing.com2 min